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HDR brachytherapy in soft tissue sarcomas allows increase dose treatment
P. Navarrete Solano1, E. Villafranca1, P. Romero1, A. Sola1, M. Rico1, C. Eito1, M. Errasti 1, G. Asin1,
M. Dominguez1, J. Sánchez Villares2, J. López Blasco1, V. Baranda2, J. Ruiz1
1 Complejo Hospitalario de Navarra, Oncología Radioterápica, Spain
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Background. Treatment with radiation therapy associated to sparing limb surgery in soft tissue sarcomas has shown a clear beneﬁt
in improving local control and survival in high grade tumors; the best radiation therapy technic is still debating.
Purpose. To evaluate response and toxicity of patients treated with HDR brachytherapy at Navarra Hospital.
Methods. Between2009and2012, 22patientsunderwent spearing limbsurgery andperioperative brachytherapy20Gy in5 fractions
or intraoperative brachytherapy for recurrent disease 10Gy in one fraction; plus adjuvant external beam radiotherapy (EBRT)
50Gy(3D or IMRT) or neoadjuvant 45Gy. Acute and late radiation toxicity was scored by CTCAE v4.0 criteria.
Results. The median age was 57 years. Most of them had adipocitic tumors (27%) followed by ﬁbrohistiocytic (22.7%), ﬁbroblastic
(13.6%), uncertain differentiation (13.6%), peripheral nerves sheath (9.1%), locally aggressive intermediate grade tumors (9.1%)
and leiomyosarcoma (4.5%). The median tumor size was 8.25 cm. 31% were stage IB, 18.2% were IIA and 13.6% III. 73.6% were
located in the lower limbs and 22.7% in the superﬁcial trunk. Brachytherapy: 19 patients perioperative and 3 intraoperative;
20 patients had adjuvant EBRT and 2 neoadjuvant. Acute toxicity grade 2 or superior: 9.1%(2p) had G3 infection, G2 and G4
dehiscence in 4.5% for both, G2 necrosis in 4.5%, G2 haematoma in 4.5%, G2–G3 radiodermitis: 35%. Late toxicity was detected
in 2p: G2 pain 4.5%, lymphedema G2–G3 9.1% and 18.2% respectively, G2 neuritis in 4.5%. Acute or late toxicity did not correlate
with PTV volume neither Homogeneity Index. Only 18% of all patients had local recurrence; 13.6% and 4.5% of them had a second
and third recurrence respectively. Systemic recurrence was seen in 2 patients, one dead by disease. Local disease free survival
at 2 years was 83%.
Conclusion. HDR brachytherapy is a safe procedure with low rate of toxicity even increasing total dose directly in the tumor bed
and shorting whole treatment time.
http://dx.doi.org/10.1016/j.rpor.2013.03.027
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Purpose & objectives. PBI is an alternative modality of treatment suitable for patients with low-risk early breast cancer after
conservative surgery. Herein, we describe the complete procedure for PBI.
Material & methods. A complete description of the implantation, planning and treatment technique for PBI is described based on
a recent case performed in our department. A 78 years old lady underwent on Monday to the operating theatre for implantation,
under local anaesthesia, of 16 wires of 18 cm long, located in 3 planes according to the rules described by the Paris system. After-
ward, steel needles were replaced by plastic tubes and a CT scan of the whole breast for physical planning purpose was acquired.
A total dose of 34Gy was prescribed in 8 fractions of 4Gy, b.i.d. with at least six hours apart between fractions. Brachytherapy
was delivered by using an HDR-Microselectron (Nucletron) afterloader under the radiotherapist supervision. The patient was
in-ward during a whole week. After delivering of the 8th fraction, plastic tubes were removed and the patient was discharged
without any complications.
Results. Rationale for PBI relies on the well-known fact that most of ipsilateral breast local relapses are located on, or in the
immediate vicinity, of the surgical bed. This modality of brachytherapy allow us to reduce total treatment time from the standard
3 weeks to 1 week and contributes to a better quality of life for the patients. However, we only consider PBI for those patients
that meet the GEC-ESTRO criteria of low-risk and therefore suitable for this sort of treatment.
Conclusions. PBI is an attractive alternative to whole breast radiotherapy, especially in those cases of low-risk breast cancer.
http://dx.doi.org/10.1016/j.rpor.2013.03.028
HDR-BRT boost in breast cancer. Does hypofractionation inﬂuence toxicity?
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Introduction. The role of brachytherapy (BRT) boost in the management of breast cancer treated conservatively is more than
consolidated.
Objectives. To evaluate our results in terms of toxicity and conﬁrm the hypothesis that it is the same whether the fractionation of
thewhole breast radiotherapy administered previously is conventional (46–50Gy/23–25 sessions) or hypofractionated (40.05Gy/15
sessions).
reports of practical oncology and radiotherapy 1 8 ( 2 0 1 3 ) S141–S163 S149
Materials and methods. We evaluated all the patients who received a High Dose Rate (HDR) boost in our department
between October 2008 and September 2012. All of them were treated with external radiotherapy to the whole breast
before the boost. We evaluated acute and long term toxicity. Then, we compared the results between the women treated
in a conventional way versus hypofractionated patients. Prescription dose was based on the modiﬁed Paris dosimetry
treatment.
Results. We treated 379 boosts. 67.3% were hypofractionated and 32.7% were conventional treatments. 50.4% were right
breast cancers and the tumor bed was localized in upper external quadrant in 37.5% of patients. 59.9% received an 8Gy
boost. The mean implant volume (isodose of the 90% of the prescribed dose) was 8.68 cm3. Regarding toxicity, our results
do not differ much more than the presented in literature. We have less than 5% acute toxicity in terms of infection,
bleeding or acute pain. Chronically, most of the patients experience different grades of pain associated to ﬁbrosis, but it
doesn’t inﬂuence their daily lives in the majority of them. No grade 3 or 4 toxicity was reported. If we compare the results
between the groups (conventional and hypofractionated), we did not ﬁnd any statistically signiﬁcant difference in terms of
toxicity.
Conclusion. HDR-BRT is a safe and not much toxic way to administer the boost over the tumor bed in patients in indication. The
ﬁnal toxicity outcomes are not inﬂuenced by the fractionation of the previous whole breast treatment.
http://dx.doi.org/10.1016/j.rpor.2013.03.029
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Introduction. Adjuvant vaginal brachytherapy in gynaecological cancer alone or combined with EBRT is a standard procedure. The
vaginal brachytherapy HDR alone with 192 Ir is a technique with minimal side effects, can be performed in an outpatient. In
patients with limited disease in endometrial, vaginal and cervix uterine. The aim of our study is to describe our experience with
vaginal brachytherapy alone.
Materials and methods. We retrospectively analyzed 130 patients diagnosed with endometrial, vagina and cervix cancer. Between
January 2008 and January 2013. Treated with brachytherapy alone. We performed a descriptive study of our patients.
Results. 130 patients mean age 63.5 (32–85). 93.8% with endometrial cancer, cervix 4.6% and 1.5% vaginal cancer. Distributed
under the current classiﬁcation of FIGO. The mean follow-up 34.7 months (7–65), 90% adenocarcinoma, and 96.9% G1–G2. Mostly
without lymphovascular inﬁltration. Treated with postoperative vaginal brachytherapy alone, mean dose 24.2Gy (24–40), mean
of 6 fractions. Delimiting organs at risk as the bladder and rectum, with a mean dose of 11.8% and 7.8% respectively. 41.5% had
some degree of mucositis, of these only 3% were G3. In 2.3% of cases occurred surgical scar dehiscence during treatment. 96.9%
live free of disease, free of symptoms in 85.4%. 12.3% have some degree of dyspareunia or vaginal stricture. Only one patient was
treated in a palliative way for an unresectable tumour, staying without illness until date. 1 death for a no speciﬁc cancer reason.
Only 4 patients had recurrence (3.1%), 2 in the lung and 2 locally.
Conclusions. In our series, the recurrence rate is low, but we have found a relation between pathological stage and tumour grade.
Not with tumour size. Vaginal brachytherapy adjuvant to surgery in patients with early stage gynaecologic tumours and low
grade offers excellent overall survival and disease-free with very low toxicity.
http://dx.doi.org/10.1016/j.rpor.2013.03.030
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Esophageal cancer (EC) is a rare tumor, very virulent and rarely curable. 50% of patients have metastatic disease at diagnosis and
50% have advanced locoregional disease. Advanced EC is a poor progression-free survival (PFS) in most of patients. Therefore the
treatment intention is palliation rather than curative. High dose rate intraluminal brachytherapy (HDR-ILBRT) allows quick and
lasting palliation and increase local control rates associated with radiochemotherapy (RCHT) in unresectable or advanced EC. The
aim of our study is evaluate symptomatic relief (pain, dysphagia) and local control in terms of PFS in unresectable or advanced
EC treated with HDR-ILBRT. Analyze secondary toxicities and the need for new treatment for recurrent dysphagia. We evaluated
between 2008 and 2012, seven patients diagnosed with unresectable or advanced EC who underwent HDR-ILBRT in our service.
Three of seven patients were treated with palliative brachytherapy (BT) and four received BT associated with RCHT (Boost).
The average dose prescribed for both treatments was 10Gy in 2 fractions, one per week. The variables studied were dysphagia
improvement, pain relief, secondary toxicities, new treatment for recurrent dysphagia and local progression-free survival in
patients treated with BT associated with RCHT. We observed that pain was relieved in all cases, dysphagia improvement in six
of them and only one required PEG. The most common acute toxicity was esophagitis G1 keeping one of them NGT after BT.
There was no bleeding or perforation. Esophageal stricture appeared as late toxicity in one patient at 5 months of completing
treatment. No endoscopic approach was necessary after BT. The mean local PFS time was 4 months for those treated with BT
